Description
Springer New Drugs in Cancer Chemotherapy 1st Editon 2013 Softbound by S.K. Carter, Y. Sakurai, H. Umezawa
The Analog Potential in Cancer Chemotherapy in the United States and Japan S. K. Carter Northern California Cancer Program, 1801 Page Mill Road, Building B, Suite 200, USA - Palo Alto, CA 94304 The bilateral collaborative program in cancer research between Japan and the United States is one of the oldest programs of this type. It is sponsored in the United States by the National Cancer Institute [1], while in Japan the sponsoring organization is the Japan Society for the Promotion of Science. Annual symposia concerning treatment have been held and in recent years they have been published [2, 3]. Drug development in both Japan and the United States has evolved over the years to an increasing emphasis on second generation compounds. This has come about as a result of the initial successes of chemotherapy development. Many active structures have been uncovered and the armamentarium of the medical and pediatric oncologist has grown dramatically. The uncovering of an active structure provides an opportunity for analog synthesis and attempts at elucidating structure-activity relationships. It is hoped that the therapeutic index of active structures can be improved so as to achieve superior clinical results. The Analog Potential in Cancer Chemotherapy in the United States and Japan.- Anthracyclines.- Preclinical Rationale and Phase I Clinical Trial of the Adriamycin Analog, AD 32.- Available Data from Carminomycin Studies in the United States: The Acute Intermittent Intravenous Schedule.- New Anthracycline Antibiotic Aclacinomycin A: Experimental Studies and Correlations with Clinical Trials.- Bleomycins.- Current Status of PEP Bleomycin Studies in Japan.- Phase I and II Study of a New Bleomycin Analog (Pepleomycin).- Tallysomycin, A Third Generation Bleomycin Analog.- Fluorinated Pyrimidines.- Studies of Analogs of Fluorinated Pyrimidine in Japan.- The Pharmacology of Ftorafur (R, S-l-(Tetrahydro-2- Furanyl)-5-Fluorouracil).- Nitrosoureas.- Current Status of Nitrosoureas Under Development in Japan.- PCNU Phase I Study in the Northern California Oncology Group.- Molecular Pharmacology of Nitrosoureas.- Mechanistic Approaches to New Nitrosourea Development.- Other New Drugs.- New Natural Products Under Development at the National Cancer Institute.- A Prospective Screening Program: Current Screening and its Status.- Selected Anticancer Drugs in Phase I Trials in the United States (1979-1980).- Fundamental Studies on Bestatin: A Small Molecular Microbial Product Enhancing Immune Responses.- A Review of Clinical Studies on Bestatin, 1976-1978.- Phase I-II Study of N4-Behenoyl-1-?-D-Arabino-furanosylcytosine.- Gastric Cancer.- The FAM Regimen for Gastric Cancer: A Progress Report.- Adjuvant Studies in Gastric Cancer in the United States.- Preliminary Results of a United States-Japan Cooperative Trial in Patients with Disseminated Gastric Cancer.- Oat Cell Lung Cancer.- Combined Modality Studies on Small Cell Carcinoma of the Lung- Current Status in Japan.- Small Cell Lung Carcinoma - Recent Advances and Current Challenges.- Head and Neck Cancer.- Combination Chemotherapy of Head and Neck Cancer in the United States.- High-Dose Methotrexate and Cis-Platinum in the Treatment of Recurrent Head and Neck Cancer.- Breast Cancer.- Current Strategy in the Chemotherapy of Advanced Breast Cancer.- Recent Advances in Chemotherapy for Advanced Breast Cancer.- The Current Status of Adjuvant Chemotherapy in Breast Cancer.